Symptom Monitoring App Use Associated With Medication Adherence Among Woman Survivors of Breast Cancer on Adjuvant Endocrine Therapy
- 1 December 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 8 (8) , e2400179
Abstract
PURPOSE: Oral adjuvant endocrine therapy (AET) reduces the risk of cancer recurrence and death for women with hormone receptor–positive (HR+) breast cancer. Because of adverse symptoms and socioecologic barriers, AET adherence rates are low. We conducted post hoc analyses of a randomized trial of a remote symptom and adherence monitoring app to evaluate characteristics associated with higher app use, satisfaction, and how app use was associated with AET adherence. METHODS: Patients prescribed AET were randomly assigned to receive one of three intervention conditions: app, app + feedback, or enhanced usual care. Baseline and 6-month follow-up surveys, app use, and pillbox-monitored AET adherence data for app and app + feedback participants were used. Logistic regression evaluated the association between sociodemographic/clinical characteristics and app utilization and satisfaction, and how app use was associated with AET adherence (>80%). RESULTS: Overall, 163 women with early-stage HR+ breast cancer were included; 35.0% had high app use (≥75% of weeks enrolled). No sociodemographic characteristics were associated with app use. Satisfaction with the app was higher among those who were younger (88.9% for age 31-49 years v 54.9% for age 65+ years, P < .001), identified as White (76.8% v 60.1% for Black, P = .045), had lower health literacy (85.4% v 68.2% with higher health literacy, P = .017), or were nonurban residents (85.7% v 68.6% for urban, P = .021). Most participants (90.3%) with high app use were AET-adherent compared with 66.8% for those with lower app use ( P < .001). CONCLUSION: Use of a remote monitoring app was similar across sociodemographic characteristics, and more frequent app use was associated with a higher likelihood of 6-month AET adherence. Encouraging women to monitor medication adherence and communicate adverse symptoms could improve AET adherence.Keywords
This publication has 38 references indexed in Scilit:
- Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast CancerJAMA Network Open, 2024
- “Interventions to increase adherence to oral therapies in breast cancer patients: A systematic review based on the behavior change technique taxonomy”Psycho-Oncology, 2023
- Breast Cancer Disparities and the Digital DivideCurrent Breast Cancer Reports, 2022
- Digital health for optimal supportive care in oncology: benefits, limits, and future perspectivesSupportive Care in Cancer, 2020
- Patient Characteristics Associated With Choosing a Telemedicine Visit vs Office Visit With the Same Primary Care CliniciansJAMA Network Open, 2020
- Digital interventions to facilitate patient‐provider communication in cancer care: A systematic reviewPsycho-Oncology, 2019
- Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trialJournal of Cancer Survivorship, 2018
- Mobile Telephone Text Messaging for Medication Adherence in Chronic DiseaseJAMA Internal Medicine, 2016
- Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancerCancer Medicine, 2012
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010